The experimental mRNA-based drug sharply reduced the risk of recurrence or death when combined with immunotherapy Keytruda, ...
A new report from the Skin Cancer Foundation predicts that 234,680 cases of melanoma will be diagnosed in the US in 2026, a ...
Five years ago, a group of high-risk skin cancer patients received a bespoke vaccine. The data is finally in, and the results ...
Long-term follow-up data from a phase 2b trial of Moderna and MSD's mRNA-based vaccine against melanoma, intismeran autogene (mRNA-4157), show an impressive 49% reduction in the risk of disease ...
By Kamal Choudhury and Mariam Sunny Jan 20 (Reuters) - Moderna and Merck said on Tuesday their experimental personalized ...
The Missouri Cancer Registry and Research Center, from 2019 to 2022, ranks Missouri 20th nationwide in melanoma deaths.
What if the earliest signs of skin cancer could be identified sooner—before a dermatology appointment?
In a small clinical trial, customized mRNA vaccines against high-risk skin cancers appeared to reduce the risk of cancer recurrence and death by nearly 50 percent over five years when compared with ...
Patients with severe melanoma who received the treatment were 49% less likely to die or have their cancer return, ...
A personalized cancer treatment developed by Moderna Inc. and Merck & Co. helped prevent the recurrence of high-risk skin ...
After a routine skin check found basal cell carcinoma on her scalp, Stacia Naquin shares her story to stress early detection ...
Jan 20 () - Moderna and Merck said on Tuesday their experimental vaccine for a serious type of skin cancer, used in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback